TuHURA Biosciences (HURA) Expected to Announce Quarterly Earnings on Friday

TuHURA Biosciences (NASDAQ:HURA) is expected to post its Q3 2026 results on Friday, November 13th. Analysts expect TuHURA Biosciences to post earnings of ($0.14) per share for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 20, 2026 at 12:30 PM ET.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. On average, analysts expect TuHURA Biosciences to post ($0.57) EPS for the current fiscal year and ($0.60) EPS for the next fiscal year.

TuHURA Biosciences Price Performance

Shares of TuHURA Biosciences stock opened at $1.51 on Wednesday. The firm has a market cap of $96.23 million, a PE ratio of -2.80 and a beta of -0.23. TuHURA Biosciences has a 12-month low of $0.41 and a 12-month high of $3.43. The company has a quick ratio of 0.18, a current ratio of 0.18 and a debt-to-equity ratio of 0.20. The company’s fifty day simple moving average is $1.96 and its two-hundred day simple moving average is $1.99.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HURA. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of TuHURA Biosciences in a research note on Tuesday, October 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, October 15th. Finally, Citizens Jmp restated a “market outperform” rating and set a $9.00 price target on shares of TuHURA Biosciences in a report on Tuesday, August 18th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

About TuHURA Biosciences

TuHURA Biosciences, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies. TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.